Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | January 6, 2028 (Listing closes)
Funding Amounts: No budget cap; project periods up to 5 years; $2.5 million planned for 5–8 additional awards in FY 2025
Summary: Supports investigator-initiated basic and early translational research in emerging areas of nonmalignant hematology.
Key Information: Clinical trials are not allowed; foreign organizations and non-U.S. components of U.S. organizations cannot apply.
Description
The Stimulating Hematology Investigation: New Endeavors (SHINE) program supports innovative, high-quality nonmalignant hematology research through investigator-initiated R01 grants. Participating NIH institutes are the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute (NHLBI), and National Institute on Aging (NIA). Research must address the program’s specified basic and early translational hematology topics, which change over time through notices linked to the announcement.
SHINE aims to catalyze molecular and cellular discoveries that improve understanding of the pathogenesis, prevention, detection, and potential treatment of nonmalignant hematologic diseases. It also seeks to attract new investigators, foster interdisciplinary collaborations, and support timely, high-impact research addressing emerging knowledge gaps.
